🎉 M&A multiples are live!
Check it out!

Tevogen Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Tevogen Bio and similar public comparables like Vivoryon Therapeutics, Julphar, and Benevolent AI.

Tevogen Bio Overview

About Tevogen Bio

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (“CD8+ CTLs” or “CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.


Founded

2021

HQ

United States of America
Employees

18

Website

tevogen.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$203M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Tevogen Bio Financials

Tevogen Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Tevogen Bio achieved revenue of n/a and an EBITDA of -$13.1M.

Tevogen Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Tevogen Bio valuation multiples based on analyst estimates

Tevogen Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$13.1M n/a XXX XXX XXX
EBITDA Margin -Infinity% NaN% XXX XXX XXX
Net Profit -$22.0M -$0.1M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt $33.8M $1.6M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Tevogen Bio Stock Performance

As of April 15, 2025, Tevogen Bio's stock price is $1.

Tevogen Bio has current market cap of $193M, and EV of $203M.

See Tevogen Bio trading valuation data

Tevogen Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$203M $193M XXX XXX XXX XXX $-0.34

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Tevogen Bio Valuation Multiples

As of April 15, 2025, Tevogen Bio has market cap of $193M and EV of $203M.

Tevogen Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Tevogen Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Tevogen Bio and 10K+ public comps

Tevogen Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $203M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -19.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Tevogen Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Tevogen Bio Valuation Multiples

Tevogen Bio's NTM/LTM revenue growth is n/a

Tevogen Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.0M for the same period.

Over next 12 months, Tevogen Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Tevogen Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Tevogen Bio and other 10K+ public comps

Tevogen Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $3.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Tevogen Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Tevogen Bio M&A and Investment Activity

Tevogen Bio acquired  XXX companies to date.

Last acquisition by Tevogen Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Tevogen Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Tevogen Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Tevogen Bio

When was Tevogen Bio founded? Tevogen Bio was founded in 2021.
Where is Tevogen Bio headquartered? Tevogen Bio is headquartered in United States of America.
How many employees does Tevogen Bio have? As of today, Tevogen Bio has 18 employees.
Who is the CEO of Tevogen Bio? Tevogen Bio's CEO is Dr. Ryan Saadi, M.D.,M.P.H..
Is Tevogen Bio publicy listed? Yes, Tevogen Bio is a public company listed on NAS.
What is the stock symbol of Tevogen Bio? Tevogen Bio trades under TVGN ticker.
When did Tevogen Bio go public? Tevogen Bio went public in 2024.
Who are competitors of Tevogen Bio? Similar companies to Tevogen Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Tevogen Bio? Tevogen Bio's current market cap is $193M
Is Tevogen Bio profitable? Yes, Tevogen Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.